Trial Profile
An Open-label Phase 1 of Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Platinum Resistant Epithelial Ovarian Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Doxorubicin liposomal (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Acronyms PEMBOV
- 06 Jun 2023 Results assessing Bevacizumab exposure and tumor response in patients with platinum resistant epithelial ovarian cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 10 Feb 2023 Planned End Date changed from 1 Jun 2024 to 1 Apr 2023.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology